Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →A peptide source is where a peptide comes from before it reaches a patient. In the U.S., lawful human-use sources are FDA-approved peptide drugs or licensed prescribers working with 503A compounding pharmacies or 503B outsourcing facilities. “Research-use-only” peptide websites are not legal sources for human use [1].
What does “peptide source” actually mean?
Peptide source means the lawful and physical path a peptide takes from manufacturing to patient use. For human use, the source matters because drugs must meet legal standards for prescribing, labeling, purity, sterility, and reporting of safety problems [1].
A peptide is a short chain of amino acids. Some peptides are FDA-approved drugs. Others are compounded for a specific patient when allowed by federal and state law. Many products sold online as research-use-only chemicals are not medicines and should not be used by people [1].
This difference is important because a vial can look professional and still be the wrong kind of source. A certificate of analysis alone does not make a product legal for human use, and it does not replace clinician oversight, sterile handling, or pharmacy accountability [1].
What are the legitimate sources of peptides in the U.S.?
Legitimate peptide sources for patients usually fall into three categories: FDA-approved drugs, 503A compounding pharmacies, and 503B outsourcing facilities. Research chemical suppliers may sell materials for laboratory use, but they are not lawful sources for human peptide therapy [1,2].
| Source type | What it means | Can patients use it? | Key safeguards |
|---|---|---|---|
| FDA-approved peptide drug | A drug reviewed by FDA for a labeled use, with approved prescribing information | Yes, when prescribed for an appropriate patient | FDA-reviewed labeling, manufacturing standards, adverse-event reporting [4] |
| 503A compounding pharmacy | A state-licensed pharmacy that compounds a prescription for an identified patient | Yes, when ordered by a licensed prescriber and allowed by law | Patient-specific prescription, pharmacist oversight, state board oversight, federal limits [2] |
| 503B outsourcing facility | An FDA-registered facility that can compound sterile drugs without patient-specific prescriptions under section 503B | Usually through health systems, clinics, or providers | FDA registration, inspections, current good manufacturing practice requirements [5] |
| Research-use-only supplier | A seller of chemicals labeled for laboratory research, not for diagnosis or treatment in people | No | Not approved or labeled for human use; not a lawful patient source [1] |
FDA-approved peptide drugs
An FDA-approved peptide drug has an approved label that lists its indication, dosing schedule, contraindications, warnings, and known adverse reactions. For example, Vyleesi (bremelanotide, also called PT-141) is FDA-approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women; its label also warns against use in patients with uncontrolled hypertension or known cardiovascular disease [4].
503A compounding pharmacies via a licensed prescriber
A 503A compounding pharmacy can prepare a medication for an individual patient after a licensed clinician writes a prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions for this pathway, including limits on compounding drugs that are essentially copies of commercially available products [2].
Compounded medications are not FDA-approved. That means FDA does not review each compounded formulation for safety, effectiveness, or quality before it reaches a patient, even when the pharmacy is properly licensed [1].
503B outsourcing facilities
A 503B outsourcing facility is different from a 503A pharmacy. It registers with FDA, may compound sterile drugs without patient-specific prescriptions, and is subject to FDA inspection and current good manufacturing practice requirements [5].
Patients usually do not order directly from a 503B facility. Instead, clinics, hospitals, and medical offices may obtain certain compounded sterile products from these facilities when lawful and clinically appropriate [5].
Research chemical suppliers, not for human use
Research-use-only chemicals are sold for laboratory research, not for diagnosis, treatment, or prevention of disease in humans. If a website sells BPC-157, TB-500, CJC-1295, ipamorelin, Semax, or similar peptides as “not for human consumption,” that label means it is not a lawful patient source [1].
Which peptides can a licensed provider prescribe today?
Prescription peptides may be FDA-approved for a labeled use or compounded when permitted by law. A licensed clinician still has to decide whether any peptide is appropriate, because side effects, contraindications, pregnancy status, cancer history, heart risk, medication interactions, and lab results may change the risk-benefit balance [1,4].
Sermorelin
Sermorelin is a growth hormone-releasing hormone analog. It is not currently FDA-approved as a marketed drug for longevity, anti-aging, fat loss, or performance; when discussed for those uses, it should be viewed as a non-FDA-approved use that requires clinician review [1].
Potential side effects reported with growth-hormone-axis therapies can include injection-site reactions, swelling, joint discomfort, glucose changes, and headaches. People with active cancer, certain endocrine disorders, pregnancy, or uncontrolled metabolic disease need careful medical review before any growth-hormone-axis therapy is considered [6].
PT-141, bremelanotide, Vyleesi
PT-141 is bremelanotide, sold as Vyleesi. Vyleesi is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women, not for sexual performance in men, bodybuilding, or general wellness [4].
In clinical trials described in the FDA label, common adverse reactions included nausea, flushing, injection-site reactions, headache, and vomiting. The label states that Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease because it can transiently increase blood pressure and reduce heart rate after use [4].
Gonadorelin
Gonadorelin is a gonadotropin-releasing hormone, also called GnRH. It has been used in diagnostic and reproductive medicine settings, but it is not FDA-approved for bodybuilding, testosterone “optimization,” or longevity uses [7].
Because gonadorelin affects reproductive hormones, side effects and risks can include headache, flushing, abdominal discomfort, ovarian stimulation concerns in some settings, and changes in sex-hormone levels. It should only be considered with clinician oversight and appropriate lab monitoring [7].
NAD+ and glutathione
NAD+ and glutathione are not peptides, but they are often grouped with peptide and longevity protocols. They are not FDA-approved to treat aging, fatigue, or general wellness, and any compounded use should be reviewed by a clinician [1].
Possible adverse effects depend on the route and formulation and may include nausea, flushing, headache, dizziness, injection-site reactions, and allergic reactions. Sterile compounded injections also carry risks if prepared or handled improperly, which is why pharmacy source and clinical oversight matter [1,5].
Which peptides are under FDA review and when?
FDA peptide review is active for several bulk drug substances used in compounding. Some longevity peptides are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026; this does not mean they are FDA-approved or guaranteed to become compoundable [3].
The July 2026 advisory committee list
FDA’s Pharmacy Compounding Advisory Committee, or PCAC, is scheduled to discuss certain nominated bulk drug substances for possible inclusion on the 503A Bulks List on July 23-24, 2026 [3]. Peptides discussed in this review pathway may include BPC-157, TB-500 or thymosin beta-4, KPV, MOTS-C, DSIP, Semax, Epitalon, and thymosin alpha-1, depending on the final FDA agenda and docket materials [3].
These peptides are not FDA-approved for the uses many consumers search for online, such as tissue repair, recovery, immune support, or longevity. Early research may explore mechanisms, but benefit claims must be weighed against unknown human safety, sterility risks, product-quality risks, and the lack of FDA-approved labeling [1,3].
The February 2027 review, including GHK-Cu
GHK-Cu, also called copper peptide GHK-Cu, is commonly discussed for skin and hair research. It is not FDA-approved for anti-aging, hair growth, wound healing, or longevity use, and future FDA review would not guarantee approval or clinical availability [1,3].
Peptides that were declined, including CJC-1295 and ipamorelin
CJC-1295 and ipamorelin are growth-hormone-axis peptides that are often marketed online, but they are not FDA-approved for anti-aging, bodybuilding, fat loss, or wellness. FDA has evaluated many nominated bulk substances through its compounding process, and substances not placed on a lawful compounding pathway should not be treated as legal patient-source products [1,8].
Why are “research-use-only” peptide sites not a legal source for people?
Research-use-only peptides are not labeled, approved, or quality-controlled as medicines for patients. The phrase “not for human consumption” is a warning that the product is not intended to diagnose, treat, or affect the body of a person [1].
A research seller may advertise purity testing or a certificate of analysis. That can be useful for laboratory buyers, but it does not create a prescription, prove sterility for injection, confirm correct storage, or provide medical screening for contraindications [1,5].
This is especially important for injectable products. Sterile compounded drugs must be prepared under strict conditions because contamination, wrong concentration, endotoxins, or dosing errors can cause serious harm [5,9].
How do I tell a legitimate peptide source from a marginal one?
A legitimate peptide source should be able to show a lawful prescribing and pharmacy pathway. Look for clinician evaluation, a named licensed pharmacy or registered outsourcing facility, clear labeling, follow-up, and a way to report side effects [1,2,5].
- Licensed clinician oversight: you should complete a health history, medication review, and risk screening before any prescription is considered [1].
- Named pharmacy partner: a real 503A pharmacy should be state-licensed, and a 503B outsourcing facility should appear on FDA’s registered outsourcing facility list [5].
- Appropriate labs and follow-up: some hormone-axis or metabolic therapies may require baseline labs and monitoring, depending on the peptide and patient risk [6,7].
- Transparent sourcing: the provider should explain whether the product is FDA-approved, compounded, or not available for human use [1].
- Clear adverse-effect information: benefits should never be presented without side effects, contraindications, and reasons a person may not qualify [4].
- No research-only workaround: a site that says “not for human consumption” while implying personal use is not a lawful patient source [1].
How do I get peptides through a licensed provider?
Getting peptides legally starts with a clinical evaluation, not a product page. A licensed provider reviews your medical history, current medications, goals, contraindications, and whether an FDA-approved or compounded option is lawful and appropriate [1,2].
For compounded medications, a 503A pharmacy prepares a patient-specific prescription after a clinician determines eligibility. Some telehealth providers, including Chia, offer clinician-reviewed access to compounded GLP-1 peptides such as semaglutide and tirzepatide through licensed 503A pharmacy partners, as well as select longevity-peptide evaluations where allowed by law [1,2].
GLP-1 peptides include semaglutide and tirzepatide. FDA-approved versions have specific labeled uses and warnings, while compounded semaglutide or compounded tirzepatide is not FDA-approved and should only be considered through a licensed prescriber and pharmacy pathway when legally available [1,10,11].
Compounded GLP-1s and longevity peptides are not the same as research chemicals. The legal pathway, pharmacy standards, prescription labeling, and follow-up process are different, even when the active ingredient name looks similar online [1,2,5].
3-min quiz
Considering peptide therapy?
A licensed clinician can review your goals, health history, medications, and labs to see whether an FDA-approved or compounded option may be appropriate.
What is the difference between compounded peptides and research chemicals?
Compounded peptides are prepared by a pharmacy after a valid prescription when allowed by law. Research chemicals are sold for laboratory use and are not legal medicines for people [1,2].
| Question | Compounded peptide | Research-use-only peptide |
|---|---|---|
| Is it for human use? | Yes, if lawfully prescribed and compounded for a patient | No; labeled for laboratory research only [1] |
| Who decides eligibility? | A licensed clinician | No clinician evaluation required by the seller |
| Who prepares it? | A licensed 503A pharmacy or FDA-registered 503B facility, depending on setting [2,5] | A chemical supplier, not a patient pharmacy |
| Is it FDA-approved? | Compounded drugs are not FDA-approved, though they may use FDA-approved ingredients when allowed [1] | No |
| What about safety information? | Should include side effects, contraindications, and follow-up | Often lacks patient labeling and medical monitoring |
Frequently asked questions
For human use in the U.S., legal access generally requires an FDA-approved prescription product or a licensed clinician working with a lawful 503A compounding pharmacy or 503B outsourcing facility. Research-use-only websites are not legal sources for people [1,2,5].
Research peptides are not approved, labeled, or quality-controlled as medicines for human use. They may lack sterile handling, correct concentration, patient instructions, side-effect reporting, and clinician screening [1,5].
BPC-157 is not FDA-approved for tissue repair, gut health, pain, longevity, or recovery. It is currently under FDA review for compounding-list questions, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026; this is not a guarantee of approval or availability [3].
Some peptide drugs are FDA-approved for specific labeled uses, such as bremelanotide, sold as Vyleesi, for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Other peptides may be compounded only when allowed by federal and state law and when a clinician determines they are appropriate [2,4].
No. A certificate of analysis may report lab testing, but it does not prove the product is lawful for human use, sterile for injection, correctly prescribed, or safe for your health history [1,5].
The FDA Pharmacy Compounding Advisory Committee, or PCAC, advises FDA on certain compounding issues, including whether nominated bulk drug substances should be included on lists used in compounding policy. PCAC discussion does not equal FDA approval [3,8].
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides eligibility, and no peptide should be used without appropriate medical review.
No. FDA-approved semaglutide and tirzepatide products have FDA-reviewed labels. Compounded semaglutide and compounded tirzepatide are not FDA-approved, even when prepared by a licensed pharmacy, and should only be considered through a lawful prescription pathway [1,10,11].
3-min quiz
Talk with a licensed clinician
If you are comparing peptide sources, start with a medical review. A clinician can explain what is approved, what is compounded, what is still under FDA review, and what may not be appropriate for you.
References
- 1.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, 2024.
- 2.U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 503A: Pharmacy Compounding. FDA, 2024.
- 3.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Announcement, July 23-24, 2026. FDA, 2026.
- 4.AMAG Pharmaceuticals. Vyleesi (bremelanotide injection) Prescribing Information. U.S. Food and Drug Administration, 2019.
- 5.U.S. Food and Drug Administration. Registered Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA, 2024.
- 6.Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 2011.
- 7.U.S. Food and Drug Administration. Factrel (gonadorelin hydrochloride) Prescribing Information. FDA, 2016.
- 8.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA, 2024.
- 9.U.S. Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. United States Pharmacopeia, 2023.
- 10.Novo Nordisk. Wegovy (semaglutide) Prescribing Information. U.S. Food and Drug Administration, 2024.
- 11.Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. U.S. Food and Drug Administration, 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
